Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.75
-0.04-1.06%
At close: -
$3.75
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
DiaMedica Therapeutics Analyst Ratings and Price Targets | NASDAQ:DMAC | Benzinga
DiaMedica Therapeutics Inc has a consensus price target of $8 based on the ratings of 4 analysts. The high is $10 issued by HC Wainwright & Co. on March 19, 2025. The low is $6 issued by Oppenheimer on August 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 19, 2025, November 15, 2024, and October 10, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 113.33% upside for DiaMedica Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Craig-Hallum
Lake Street
1calculated from analyst ratings
Analyst Ratings for DiaMedica Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 166.67% | HC Wainwright & Co. | Matthew Caufield38% | $7 → $10 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 86.67% | HC Wainwright & Co. | Matthew Caufield38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 86.67% | HC Wainwright & Co. | Matthew Caufield38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | 86.67% | HC Wainwright & Co. | Matthew Caufield38% | → $7 | Initiates | → Buy | Get Alert |
| 08/16/2024 | Buy Now | 60% | Oppenheimer | Francois Brisebois43% | $6 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 04/24/2024 | Buy Now | 113.33% | Craig-Hallum | Alexander Nowak63% | → $8 | Assumes | → Buy | Get Alert |
| 03/21/2024 | Buy Now | 113.33% | Craig-Hallum | Alexander Nowak63% | $11 → $8 | Maintains | Buy | Get Alert |
| 03/21/2024 | Buy Now | 60% | Oppenheimer | Francois Brisebois43% | $7 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 06/22/2023 | Buy Now | 86.67% | Oppenheimer | Francois Brisebois43% | → $7 | Upgrade | Perform → Outperform | Get Alert |
| 07/07/2022 | Buy Now | 113.33% | Lake Street | Thomas Flaten38% | $14 → $8 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | 220% | Craig-Hallum | Alexander Nowak63% | $18 → $12 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | — | Oppenheimer | Francois Brisebois43% | — | Downgrade | Outperform → Perform | Get Alert |
FAQ
What is the target price for DiaMedica Therapeutics (DMAC) stock?
The latest price target for DiaMedica Therapeutics (NASDAQ:DMAC) was reported by HC Wainwright & Co. on March 19, 2025. The analyst firm set a price target for $10.00 expecting DMAC to rise to within 12 months (a possible 166.67% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DiaMedica Therapeutics (DMAC)?
The latest analyst rating for DiaMedica Therapeutics (NASDAQ:DMAC) was provided by HC Wainwright & Co., and DiaMedica Therapeutics maintained their buy rating.
When was the last upgrade for DiaMedica Therapeutics (DMAC)?
The last upgrade for DiaMedica Therapeutics Inc happened on June 22, 2023 when Oppenheimer raised their price target to $7. Oppenheimer previously had a perform for DiaMedica Therapeutics Inc.
When was the last downgrade for DiaMedica Therapeutics (DMAC)?
The last downgrade for DiaMedica Therapeutics Inc happened on July 7, 2022 when Oppenheimer changed their price target from N/A to N/A for DiaMedica Therapeutics Inc.
When is the next analyst rating going to be posted or updated for DiaMedica Therapeutics (DMAC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DiaMedica Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DiaMedica Therapeutics was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating DiaMedica Therapeutics (DMAC) correct?
While ratings are subjective and will change, the latest DiaMedica Therapeutics (DMAC) rating was a maintained with a price target of $7.00 to $10.00. The current price DiaMedica Therapeutics (DMAC) is trading at is $3.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.